C Haioun

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

C Sebban, B. Coiffier, H. Tilly, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

J Diebold, T. Molina, P. Gaulard, 2000, Blood.

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).

J Diebold, P. Gaulard, G. Salles, 1996, Blood.

Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.

G. Salles, J. Jais, O. Casasnovas, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.